Region 3 Program: Beyond the Scales: Cardiometabolic Benefits of Today’s Anti-Obesity Agents

Participants will examine the evolving landscape of obesity pharmacotherapy with a spotlight on the cardiovascular implications of modern anti-obesity medications. The session will review current and emerging agents, summarize key clinical trials, and highlight evidence showing improvements in cardiovascular outcomes — including reductions in major adverse cardiovascular events, benefits in heart failure (especially HFpEF), and favorable effects on cardiometabolic risk factors such as blood pressure, lipids, inflammation, and glycemic control.

For more information and to register: sign in to the MNA App/events section or sign in to the MNA Member Portal at https://mna.yourassociation.org and click the CE Programs/Events button.

For questions or for nonmembers to register, please contact Liz Chmielinski, 781-830-5719